This year saw notable progress in head and neck cancers, Huntington's disease, personalized genetic therapy, and heart ...

On a video call in early September, Sarah Tabrizi first saw the data that she and other researchers studying Huntington’s ...

They manage to slow down the progression of Huntington's disease using a gene therapy treatment called AMT 130.

Investor optimism has waned as final minutes from uniQure’s pre-BLA meeting with the FDA convey that data from the company’s Phase I/II studies of AMT-130 are “unlikely” to provide the primary ...

A charity representing people with Huntington’s disease has said it is “worried and saddened” by mistreatment findings at a ...

Instead of finding treatments for one rare disease, two University at Albany researchers have developed a compound that could ...

Juvenile Huntington’s disease is more aggressive than Huntington’s disease, reducing a child’s life expectancy at a far ...

UCL and uniQure report the first treatment to slow Huntington’s disease with gene therapy AMT-130. High-dose patients had 75% less progression over three years compared with standard care. uniQure ...

Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The "Huntington's Disease Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035" report has been added to ...

Huntington’s disease is a genetic disease that is debilitating and progressive leading to severe brain damage and eventual death. In patients with this autosomal dominant disease, there is presence of ...